Pfizer’s Hit Vaccine Gets a New Market

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Vaccine Syringe Needle

Pharmaceutical giant Pfizer Inc. (NYSE:PFE) on Wednesday said it received European approval for expanded use of its Prevenar 13 antibacterial vaccine for adults aged 18 to 49 years old. The pneumococcal vaccine was previously approved in Europe for adults 50 years of age and older, as well as for infants, youth, and adolescents aged 6 weeks to 17 years old.

The vaccine is used to protect against 13 strains of the Streptococcus pneumoniae bacterium, which can cause pneumonia and meningitis.

“Prevenar 13 has been administered to millions of individuals around the world, and today’s European approval for the expanded use of Prevenar 13 is a testament to Pfizer’s continued commitment to developing innovative vaccines that can help prevent serious — and sometimes fatal — disease through every stage of life,” Pfizer’s chief scientific officer of vaccine research, Emilio Emini, said in a statement.

More Articles About:

To contact the reporter on this story: To contact the editor responsible for this story:

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business